ArticleProceedings of the National Academy of Sciences of the United States of America2023
MYC-driven synthesis of Siglec ligands is a glycoimmune checkpoint.
Open access · hybridAbstract read
In one paragraph
Article in Proceedings of the National Academy of Sciences of the United States of America, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed
9.2field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 61 citations in OpenAlex.
- From Glycocode to Precision Oncology: Therapeutic Strategies Targeting Aberrant O-GalNAc Glycosylation in Cancer.Chemical reviews · 2026Review
- Surfaceome CRISPR activation screening uncovers ligands regulating tumor sensitivity to NK cell killing.Nature communications · 2026Article
- Pharmacologic glycoengineering of Fcγ receptor IIIa enhances force-resistant IgG-FcγR interactions and anti-tumor antibody efficacy.Immunity · 2026Article
- Regulatory factor X 7 limits Myc activity during B cell activation and suppresses Myc-dependent lymphomagenesis.Nature immunology · 2026Article
- Immune implications and therapeutic opportunities of tumor glycosylation.Nature cancer · 2026Review
- Tissue-specific factors that govern the sialoglycan-Siglec axis in cancer.Bioscience reports · 2026Review
- Sialic Acids in Kidney Disease: Immune Regulation, Complement Activation and Glomerular Injury.Antioxidants (Basel, Switzerland) · 2026Review
- CRISPR activation screens map the genomic landscape of cancer glycome remodeling.Cell genomics · 2026Article
- Writers and readers of sialylation in immunoregulation in cancer.The Journal of biological chemistry · 2026Review
- Sialylation in Thyroid Carcinoma: An Overview of Mechanisms, Markers, and Therapeutic Opportunities.Journal of Cancer · 2026Review
- Drug-tolerant persister cells in lymphoid malignancies: from mechanisms to therapeutic opportunities.Frontiers in oncology · 2026Review
- YBX1 Enhances the Stability of TM4SF1 in an mCombinatorial chemistry & high throughput screening · 2026Article
- Antibody-lectin chimeras for glyco-immune checkpoint blockade.Nature biotechnology · 2025Article
- An ultrasensitive and modular platform to detect Siglec ligands and control immune cell function.Science advances · 2025Article
- Review
- MYC as a Target for Cancer Treatment: from Undruggable to Druggable?Targeted oncology · 2025Review
- Building simplified cancer subtyping and prediction models with glycan gene signatures.Cell reports methods · 2025Article
- PPDPF promotes the progression of esophageal squamous cell carcinoma via c-Myc/CD24 axis.Journal for immunotherapy of cancer · 2025Article
- Unraveling the glyco-immunity nexus in pancreatic cancer.Molecular cancer · 2025Review
- Tumor glyco-immunology, glyco-immune checkpoints and immunotherapy.Journal for immunotherapy of cancer · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 7 institutions in 2 countries.
Benjamin A H SmithSarafan ChEM-H, Stanford University, Stanford, CA 94305.ORCID 0000-0001-8802-416X
Anja DeutzmannDivision of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305.ORCID 0000-0002-3271-1427
Kristina M CorreaDepartment of Chemistry, Stanford University, Stanford, CA 94305.
Corleone S DelaverisSarafan ChEM-H, Stanford University, Stanford, CA 94305.ORCID 0000-0002-7291-2338
Renumathy DhanasekaranDivision of Gastroenterology and Hepatology, Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305.
Christopher G DoveDivision of Hematology, Department of Medicine, Stanford University, Stanford, CA 94305.
Delaney K SullivanDivision of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305.
Simon WisnovskyFaculty of Pharmaceutical Sciences, University of British Columbia, British Columbia, BC V6T 1Z3, Canada.
Jessica C StarkSarafan ChEM-H, Stanford University, Stanford, CA 94305.
John V PluvinageDepartment of Neurology, University of California, San Francisco, CA 94143.
Srividya SwaminathanDivision of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305.
Nicholas M RileyDepartment of Chemistry, Stanford University, Stanford, CA 94305.ORCID 0000-0002-1536-2966
Anand RajanDepartment of Pathology, University of Iowa, Iowa City, IA 52242.
Ravindra MajetiDivision of Hematology, Department of Medicine, Stanford University, Stanford, CA 94305.
Dean W FelsherDivision of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305.
Carolyn R BertozziSarafan ChEM-H, Stanford University, Stanford, CA 94305.ORCID 0000-0003-4482-2754
Stanford University · USCalifornia Institute for Regenerative Medicine · USCity of Hope · USHoward Hughes Medical Institute · USUniversity of British Columbia · CAUniversity of California, San Francisco · USUniversity of Iowa · US
Funding
MEDICAL SCIENTIST TRAINING PROGRAMT32GM007365 · NIGMS · STANFORD UNIVERSITY · PI CHUA, KATRIN F · 1985 to 2021
$33.8MTargeting the MYC Pathway for the Treatment of CancerR35CA253180 · NCI · STANFORD UNIVERSITY · PI DEAN W FELSHER · 2020 to 2026
$6.9MNational Glycoscience Resource- CCRC Service and Training - NGlycoR@CCRCR24GM137782 · NIGMS · UNIVERSITY OF GEORGIA · PI Parastoo Azadi · 2020 to 2026
$5.2MTargeting the Cancer GlycocalyxR01CA227942 · NCI · STANFORD UNIVERSITY · PI Carolyn Bertozzi · 2019 to 2026
$3.6MModeling and Predicting Therapeutic Resistance of CancerU01CA188383 · NCI · STANFORD UNIVERSITY · PI FELSHER, DEAN W, GAMBHIR, SANJIV S · 2014 to 2018
$3.2MPrognostic Metabolic Signatures of Cancers Through Mass Spectrometry ImagingR01CA184384 · NCI · STANFORD UNIVERSITY · PI FELSHER, DEAN W, ZARE, RICHARD N · 2014 to 2018
$2.7M(PQ7)Multi-scale Analysis of Tumor Microenvironment HeterogeneityR01CA208735 · NCI · STANFORD UNIVERSITY · PI FELSHER, DEAN W · 2017 to 2019
$2.2MMechanisms by which Oncogene Inactivation Elicits Tumor Cell DeathR01CA170378 · NCI · STANFORD UNIVERSITY · PI FELSHER, DEAN W · 2012 to 2015
$2.1MFunctional Proteomic Analysis and Biomarker Identification in a Novel Mouse Model of Metastatic Hepatocellular Carcinoma (HCC)K08CA222676 · NCI · STANFORD UNIVERSITY · PI DHANASEKARAN, RENUMATHY · 2018 to 2022
$1.0MUniting Mass Spectrometry and Glycoscience to Investigate Cancer BiologyK00CA212454 · NCI · STANFORD UNIVERSITY · PI RILEY, NICHOLAS M · 2018 to 2021
$331kBD Canto II RUO CytometerS10RR027431 · NCRR · STANFORD UNIVERSITY · PI NOLAN, GARRY P · 2010 to 2010
$236kMechanisms of Age-Related Microglial Impairment and Rejuvenation in Alzheimer's DiseaseF30AG060638 · NIA · STANFORD UNIVERSITY · PI PLUVINAGE, JOHN VINCENT · 2018 to 2020
$132kNCI NIH HHS F30 CA232541NCI NIH HHS F32 CA250324NCI NIH HHS K00 CA212454NCI NIH HHS K08 CA222676NCI NIH HHS R01 CA170378NCI NIH HHS R01 CA184384NCI NIH HHS R01 CA208735NCI NIH HHS R01 CA227942NCI NIH HHS R35 CA253180NCI NIH HHS U01 CA188383NCRR NIH HHS S10 RR027431NIA NIH HHS F30 AG060638NIGMS NIH HHS K99 GM147304NIGMS NIH HHS R24 GM137782NIGMS NIH HHS T32 GM007365
Abstract
The Siglecs (sialic acid-binding immunoglobulin-like lectins) are glycoimmune checkpoint receptors that suppress immune cell activation upon engagement of cognate sialoglycan ligands. The cellular drivers underlying Siglec ligand production on cancer cells are poorly understood. We find the
Indexed as
NeoplasmsProto-Oncogene Proteins c-mycSialic Acid Binding Immunoglobulin-like LectinsAnimalsAntigens, CDHumansLigandsMacrophagesMiceAntigens, CDLigandsMyc protein, mouseProto-Oncogene Proteins c-mycSialic Acid Binding Immunoglobulin-like LectinsglycosylationMYConcogeneSiglec
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.